Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free SABSW Stock Alerts

SAB Biotherapeutics (SABSW) Competitors

SAB Biotherapeutics logo
$0.02 0.00 (-0.50%)
As of 10:10 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

SABSW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy SAB Biotherapeutics stock or one of its competitors? SAB Biotherapeutics's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does SAB Biotherapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and SAB Biotherapeutics (NASDAQ:SABSW) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

In the previous week, Alvotech had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 2 mentions for Alvotech and 1 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 1.89 beat Alvotech's score of 0.93 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Alvotech Positive
SAB Biotherapeutics Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$559.42MN/AN/AN/AN/A
SAB BiotherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
SAB Biotherapeutics N/A N/A N/A

Summary

Alvotech beats SAB Biotherapeutics on 2 of the 3 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Apollomics?

Apollomics (NASDAQ:APLMW) and SAB Biotherapeutics (NASDAQ:SABSW) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
SAB Biotherapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
SAB BiotherapeuticsN/AN/AN/AN/AN/A

In the previous week, Apollomics had 2 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 3 mentions for Apollomics and 1 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 1.89 beat Apollomics' score of 0.29 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Apollomics Neutral
SAB Biotherapeutics Very Positive

Summary

Apollomics beats SAB Biotherapeutics on 2 of the 3 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Aravive?

SAB Biotherapeutics (NASDAQ:SABSW) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Company Net Margins Return on Equity Return on Assets
SAB BiotherapeuticsN/A N/A N/A
Aravive N/A N/A N/A

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, SAB Biotherapeutics had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for SAB Biotherapeutics and 0 mentions for Aravive. SAB Biotherapeutics' average media sentiment score of 1.89 beat Aravive's score of 0.00 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company Overall Sentiment
SAB Biotherapeutics Very Positive
Aravive Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SAB BiotherapeuticsN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

Summary

SAB Biotherapeutics and Aravive tied by winning 2 of the 4 factors compared between the two stocks.

How does SAB Biotherapeutics compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAFW) and SAB Biotherapeutics (NASDAQ:SABSW) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

Company Net Margins Return on Equity Return on Assets
bioAffinity TechnologiesN/A N/A N/A
SAB Biotherapeutics N/A N/A N/A

In the previous week, bioAffinity Technologies had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 2 mentions for bioAffinity Technologies and 1 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 1.89 beat bioAffinity Technologies' score of 0.97 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
bioAffinity Technologies Positive
SAB Biotherapeutics Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$5.61MN/AN/AN/AN/A
SAB BiotherapeuticsN/AN/AN/AN/AN/A

Summary

bioAffinity Technologies beats SAB Biotherapeutics on 2 of the 3 factors compared between the two stocks.

How does SAB Biotherapeutics compare to BioVie?

BioVie (NASDAQ:BIVIW) and SAB Biotherapeutics (NASDAQ:SABSW) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Company Net Margins Return on Equity Return on Assets
BioVieN/A N/A N/A
SAB Biotherapeutics N/A N/A N/A

In the previous week, BioVie had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 2 mentions for BioVie and 1 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 1.89 beat BioVie's score of 1.87 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
BioVie Very Positive
SAB Biotherapeutics Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/AN/AN/AN/A
SAB BiotherapeuticsN/AN/AN/AN/AN/A

Summary

BioVie and SAB Biotherapeutics tied by winning 1 of the 2 factors compared between the two stocks.

Get SAB Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SABSW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SABSW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SABSW vs. The Competition

Export
MetricSAB BiotherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$3.73B$7.03B$13.08B
Dividend YieldN/A3.76%2.58%10.74%
P/E RatioN/A10.36269.0925.22
Price / SalesN/A1,268.15642.14105.23
Price / CashN/A102.9470.5950.58
Price / BookN/A18.1913.286.25
Net IncomeN/A-$13.23M$3.45B$347.70M
7 Day PerformanceN/A2.77%2.17%1.87%
1 Month PerformanceN/A1.29%1.25%1.03%
1 Year PerformanceN/A55.09%68.01%19.90%

SAB Biotherapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SABSW
SAB Biotherapeutics
N/A$0.02
-0.5%		N/A-28.7%$0.00N/AN/A140
ALVOW
Alvotech
N/A$0.15
flat		N/AN/A$0.00$559.42MN/A4
APLMW
Apollomics
N/A$0.02
flat		N/A-29.3%$0.00$8.50MN/A59
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.07
+0.9%		N/A-30.7%$0.00$5.61MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SABSW) was last updated on 8/13/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
What's the Best Way to Lower RMD Taxes?
Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...
SmartAsset | Sponsoredtc pixel